Here, we provide a proof‐of‐principle validation of EV‐RNA and cfDNA isolated through ONCE as informative analytes for detecting the ERBB2/HER2 biomarker in a cohort of early‐stage breast cancer (BrCa) patients with tissue‐defined HER2 status. This evidence concerns the gene ERBB2 and breast carcinoma.